About this trial
The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.
Eligibility criteria
Qualifiers
Male or female over 18 years of age;
Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist;
Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP);
French-speaking patient with no comprehension difficulties;
Disqualifiers
Have previously undergone a capillaroscopy, regardless of the reason;
Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation;
Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy;
Pregnant or breastfeeding women;
Trial design
Treatments tested in this trial
- capillaroscopy